Wegovy and Mounjaro have attracted considerable attention among people looking for medical support with weight management. Both medicines can help eligible people lose weight when combined with changes to their diet and physical activity. However, they work in different ways, and neither is suitable for everyone.
In Ireland, people considering weight management medicines should speak with a qualified healthcare professional before starting treatment. A GP can assess medical history, weight-related health conditions, potential risks and whether prescription treatment may be appropriate.
This guide explains how Wegovy and Mounjaro work, who may qualify, their possible side effects and what Irish residents should know before considering either medicine.
What Is Wegovy?
Wegovy contains semaglutide, a medicine that acts on the GLP-1 receptor. This receptor is involved in regulating appetite and food intake. The medicine can help people feel fuller for longer, reduce hunger and make it easier to manage how much they eat.
Wegovy is used alongside a reduced-calorie diet and increased physical activity for weight management. Under European authorisation, eligible adults generally include those with a body mass index (BMI) of 30 or above, or a BMI of 27 or above with at least one weight-related health condition.
Wegovy is commonly administered as a once-weekly injection under the skin. The dose is increased gradually according to the prescribed schedule to help reduce gastrointestinal side effects.
It is a prescription medicine, not a general dietary supplement. Your healthcare professional should explain how to use it, what results to expect and when your progress will be reviewed.
Official European information is available at:
What Is Mounjaro?
Mounjaro contains tirzepatide, which acts on two hormone receptors: GIP and GLP-1. These pathways are involved in blood glucose regulation, appetite and food intake.
Mounjaro is authorised in the European Union for treating type 2 diabetes and, under specified criteria, for weight management in adults. For weight management, it is used alongside a reduced-calorie diet and increased physical activity.
Eligibility for adults generally includes a BMI of 30 or above, or a BMI of at least 27 but below 30 with a weight-related health condition, such as high blood pressure, abnormal blood fats or obstructive sleep apnoea.
Mounjaro is administered as a once-weekly injection. A prescriber determines the starting dose and any increases based on the approved instructions, treatment response and tolerability.
Although it can support weight loss, Mounjaro is not a quick fix. Ongoing medical review and sustainable lifestyle changes remain important.
For official details, visit:
Wegovy vs Mounjaro: What Is the Difference?
Both medicines can support weight management, but they contain different active ingredients and work through different hormone pathways.
Wegovy: Contains semaglutide and acts on GLP-1 receptors.
Mounjaro: Contains tirzepatide and acts on both GIP and GLP-1 receptors.
Both are used alongside dietary changes and physical activity, and both can cause gastrointestinal side effects. Results vary between individuals, and findings from clinical trials do not guarantee a particular outcome for any one person.
The most suitable treatment depends on factors such as medical history, other medicines, weight-related conditions, tolerability, availability and cost. It is not appropriate to choose a medicine based only on online reviews or another person’s experience.
Do not use Wegovy and Mounjaro together unless a specialist has explicitly directed your care in a way consistent with approved medical guidance. They should not be combined independently.
Who May Be Eligible in Ireland?
Weight management medicines are not suitable for everyone who wants to lose a few kilograms. Prescribers assess whether treatment is medically appropriate and whether the person meets the relevant criteria.
Your GP or specialist may consider:
- Your BMI and weight history.
- Conditions such as type 2 diabetes, high blood pressure or high cholesterol.
- Previous attempts at weight management.
- Current medicines and relevant medical conditions.
- Potential side effects and treatment goals.
- Whether you can maintain the required follow-up appointments.
Eligibility under a medicine’s authorisation does not automatically mean that it will be funded through the public health system. Availability, prescription arrangements and costs can differ. Ask your GP or pharmacist about current options in Ireland.
The HSE provides information about obesity medicines, eligibility and important safety considerations:
Possible Side Effects and Safety
Wegovy and Mounjaro can cause side effects, particularly when treatment begins or the dose increases.
Common side effects include:
- Nausea or feeling sick.
- Vomiting.
- Diarrhoea.
- Constipation.
- Abdominal discomfort or pain.
- Indigestion.
These effects vary in severity and may improve over time, but persistent symptoms should be discussed with your healthcare professional.
Severe or persistent abdominal pain, repeated vomiting or signs of dehydration require prompt medical assessment. Seek urgent medical help for a severe allergic reaction or other serious symptoms.
Before starting either medicine, tell your prescriber about your medical history, all medicines and supplements you take, and whether you are pregnant, breastfeeding or planning a pregnancy. These medicines are not intended for weight loss during pregnancy. Your prescriber can explain the relevant precautions and when treatment should be stopped or avoided.
Never change your dose independently or share an injection pen with another person.
How to Support Weight Management During Treatment
Medication works best as part of a broader, sustainable approach to health. You do not need to follow an extreme diet to make meaningful changes.
Eat balanced meals: Include vegetables, fruit, wholegrains, protein sources and suitable amounts of healthy fats. Smaller meals may be easier to tolerate if you experience nausea.
Stay hydrated: Drink water regularly, especially if you experience vomiting or diarrhoea.
Include regular activity: Walking, cycling, swimming and strength-based exercise can support general health and help preserve muscle during weight loss. Start at a manageable level and increase gradually.
Prioritise sleep: Consistent sleep routines can support energy, appetite regulation and everyday wellbeing.
Attend follow-up appointments: Your healthcare professional can review progress, side effects, nutrition and whether treatment should continue.
Avoid buying weight loss injections from social media sellers or unverified websites. Counterfeit or improperly stored medicines may pose serious risks. Obtain prescription medicines through legitimate healthcare and pharmacy channels.
Conclusion
Wegovy and Mounjaro are prescription medicines that can help eligible adults manage their weight when combined with dietary changes and increased physical activity. Wegovy contains semaglutide, while Mounjaro contains tirzepatide. Both require careful consideration of eligibility, possible side effects and individual health needs.
For people in Ireland, the first step is to discuss weight management with a GP or another qualified prescriber. They can explain the available options, assess whether medication is suitable and clarify costs and follow-up arrangements.
A safe, informed approach can help you make decisions that support your long-term health rather than focusing only on short-term weight loss.
